What is the current valuation of the US hemiplegic migraine market?

The market valuation was $0.281 Million in 2024. Read More

What is the projected market valuation for the US hemiplegic migraine market by 2035?

The projected valuation for 2035 is $0.416 Million. Read More

What is the expected CAGR for the US hemiplegic migraine market during the forecast period?

The expected CAGR for the market from 2025 - 2035 is 3.61%. Read More

Which companies are the key players in the US hemiplegic migraine market?

Key players include Amgen, Teva Pharmaceutical Industries, Eli Lilly and Company, Novartis, Pfizer, AstraZeneca, Boehringer Ingelheim, and Bristol-Myers Squibb. Read More

What are the main types of hemiplegic migraine segments in the market?

The main segments are Familial Hemiplegic Migraine and Sporadic Hemiplegic Migraine. Read More

What was the market value for Familial Hemiplegic Migraine in 2024?

The market value for Familial Hemiplegic Migraine was $0.112 Million in 2024. Read More

What is the market value for Acute treatment in the US hemiplegic migraine market?

The market value for Acute treatment was $0.084 Million in 2024. Read More

What are the primary distribution channels for hemiplegic migraine treatments?

Primary distribution channels include Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, and others. Read More

What is the projected market value for Botox Injections as a preventive treatment by 2035?

The projected market value for Botox Injections as a preventive treatment is $0.168 Million by 2035. Read More

US Hemiplegic Migraine Market

Q: What treatment options are available for hemiplegic migraine?

Available treatment options include Acute treatment, Triptans, Ergotamines, NSAIDs, Antiemetics, Narcotic Analgesics, and others. Read More

US Hemiplegic Migraine Market Research Report By Type (Familial Hemiplegic Migraine, Sporadic Hemiplegic Migraine) By End-user (Hospitals & Clinics, Diagnostic Centers, Others) By Treatment (Acute treatment, Triptans, Ergotamines, NSAIDs, Antiemetics, Narcotic Analgesics, Others) By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Others) By Preventive Treatment (Antidepressants, Botox Injections, Others) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

3.61%

2024 Market Size

$ 0.28 Million

2035 Market Size

$ 0.42 Million

Healthcare ● Updated January 2026 Report ID: MRFR/HC/16511-CR | Pages: 100 | Author: Satyendra Maurya, Garvit Vyas

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Type (USD Million)
  1. 4.1.1 Familial Hemiplegic Migraine
  2. 4.1.2 Sporadic Hemiplegic Migraine
2. 4.2 Pharmaceutical, BY Treatment (USD Million)
  1. 4.2.1 Acute treatment
  2. 4.2.2 Triptans
  3. 4.2.3 Ergotamines
  4. 4.2.4 NSAIDs
  5. 4.2.5 Antiemetics
  6. 4.2.6 Narcotic Analgesics
  7. 4.2.7 Others
3. 4.3 Pharmaceutical, BY End-user (USD Million)
  1. 4.3.1 Hospitals & Clinics
  2. 4.3.2 Diagnostic Centers
  3. 4.3.3 Others
4. 4.4 Pharmaceutical, BY Preventive Treatment (USD Million)
  1. 4.4.1 Antidepressants
  2. 4.4.2 Botox Injections
  3. 4.4.3 Others
5. 4.5 Pharmaceutical, BY Distribution Channel (USD Million)
  1. 4.5.1 Retail Pharmacies
  2. 4.5.2 Hospital Pharmacies
  3. 4.5.3 Online Pharmacies
  4. 4.5.4 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Amgen (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Teva Pharmaceutical Industries (IL)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Eli Lilly and Company (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Pfizer (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 AstraZeneca (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Boehringer Ingelheim (DE)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Bristol-Myers Squibb (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY TREATMENT
4. 6.4 US MARKET ANALYSIS BY END-USER
5. 6.5 US MARKET ANALYSIS BY PREVENTIVE TREATMENT
6. 6.6 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
7. 6.7 KEY BUYING CRITERIA OF PHARMACEUTICAL
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF PHARMACEUTICAL
10. 6.10 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
12. 6.12 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
13. 6.13 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
14. 6.14 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million)
15. 6.15 PHARMACEUTICAL, BY TREATMENT, 2024 (% SHARE)
16. 6.16 PHARMACEUTICAL, BY TREATMENT, 2024 TO 2035 (USD Million)
17. 6.17 PHARMACEUTICAL, BY END-USER, 2024 (% SHARE)
18. 6.18 PHARMACEUTICAL, BY END-USER, 2024 TO 2035 (USD Million)
19. 6.19 PHARMACEUTICAL, BY PREVENTIVE TREATMENT, 2024 (% SHARE)
20. 6.20 PHARMACEUTICAL, BY PREVENTIVE TREATMENT, 2024 TO 2035 (USD Million)
21. 6.21 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
22. 6.22 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
  3. 7.2.3 BY END-USER, 2025-2035 (USD Million)
  4. 7.2.4 BY PREVENTIVE TREATMENT, 2025-2035 (USD Million)
  5. 7.2.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Hemiplegic Migraine Market Segmentation

US Hemiplegic Migraine Market By Type (USD Million, 2025-2035)

Familial Hemiplegic Migraine
Sporadic Hemiplegic Migraine

US Hemiplegic Migraine Market By Treatment (USD Million, 2025-2035)

Acute treatment
Triptans
Ergotamines
NSAIDs
Antiemetics
Narcotic Analgesics
Others

US Hemiplegic Migraine Market By End-user (USD Million, 2025-2035)

Hospitals & Clinics
Diagnostic Centers
Others

US Hemiplegic Migraine Market By Preventive Treatment (USD Million, 2025-2035)

Antidepressants
Botox Injections
Others

US Hemiplegic Migraine Market By Distribution Channel (USD Million, 2025-2035)

Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Others

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”